Immatics (NASDAQ:IMTX - Get Free Report)'s share price hit a new 52-week low on Tuesday . The stock traded as low as $4.83 and last traded at $4.85, with a volume of 566228 shares traded. The stock had previously closed at $5.05.
Analyst Ratings Changes
IMTX has been the subject of several analyst reports. Bank of America lowered their price objective on Immatics from $16.00 to $15.00 and set a "buy" rating for the company in a research report on Tuesday, November 19th. The Goldman Sachs Group upgraded Immatics to a "strong-buy" rating in a research report on Monday, November 25th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $16.67.
Check Out Our Latest Research Report on Immatics
Immatics Stock Performance
The business has a fifty day moving average of $6.01 and a 200 day moving average of $8.64. The company has a market capitalization of $549.06 million, a PE ratio of -6.97 and a beta of 0.75.
Hedge Funds Weigh In On Immatics
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of America Corp DE boosted its holdings in Immatics by 166.0% during the 4th quarter. Bank of America Corp DE now owns 3,575 shares of the company's stock valued at $25,000 after acquiring an additional 2,231 shares during the period. Virtus ETF Advisers LLC boosted its holdings in Immatics by 34.8% during the 4th quarter. Virtus ETF Advisers LLC now owns 9,594 shares of the company's stock valued at $68,000 after acquiring an additional 2,479 shares during the period. Quarry LP boosted its holdings in Immatics by 29.4% during the 3rd quarter. Quarry LP now owns 11,000 shares of the company's stock valued at $126,000 after acquiring an additional 2,500 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in Immatics by 24.6% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 22,701 shares of the company's stock valued at $163,000 after acquiring an additional 4,477 shares during the period. Finally, Forefront Analytics LLC raised its position in Immatics by 42.3% in the 4th quarter. Forefront Analytics LLC now owns 15,911 shares of the company's stock valued at $113,000 after purchasing an additional 4,731 shares in the last quarter. 64.41% of the stock is currently owned by hedge funds and other institutional investors.
Immatics Company Profile
(
Get Free Report)
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
See Also
Before you consider Immatics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immatics wasn't on the list.
While Immatics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
